- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07228247
En fase Ⅰ/Ⅱa-studie av HMPL-A251 hos deltakere med avansert eller metastatisk HER2-uttrykkende solide svulster
En fase Ⅰ/Ⅱa-studie for å evaluere sikkerheten, tolerabiliteten, farmakokinetikken, immunogeniteten og foreløpig effekt av HMPL-A251 hos deltakere med avansert eller metastatisk HER2-uttrykkende solide svulster
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
- To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A251 in participants with previously treated HER2+ solid tumors
- To characterize the safety and preliminary efficacy of HMPL-A251 at RDEs to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected HER2-expressing solid tumors
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Colorado
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- SCRI HealthONE
-
Ta kontakt med:
- Gerald Falchook
- Telefonnummer: 940-365-6217
- E-post: bianca.reyes@scri.com
-
-
Florida
-
Plantation, Florida, Forente stater, 33322
- Rekruttering
- BRCR Global
-
Ta kontakt med:
- Harshad Amin
- Telefonnummer: 561-447-0614
- E-post: alejandrop@brcrglobal.com
-
Plantation, Florida, Forente stater, 33322
- Rekruttering
- Florida Clinical Trials Group LLC (Plantation)
-
Ta kontakt med:
- Harshad Amin
- Telefonnummer: 772-297-3057
- E-post: clinops@floridactg.com
-
Tamarac, Florida, Forente stater, 33321
- Har ikke rekruttert ennå
- Florida Clinical Trials Group LLC (Tamarac)
-
Ta kontakt med:
- Chintan Ghandi
-
-
New Jersey
-
East Brunswick, New Jersey, Forente stater, 08816
- Har ikke rekruttert ennå
- START New Jersey
-
Ta kontakt med:
- Bruno Fang
-
-
New York
-
New York, New York, Forente stater, 10065
- Har ikke rekruttert ennå
- Memorial Sloan Kettering Cancer Center
-
Ta kontakt med:
- Vicky Makker
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic Taussig Cancer Center
-
Ta kontakt med:
- WenWee Ma
- Telefonnummer: 216-559-9815
- E-post: keaneyh@ccf.org
-
-
Washington
-
Tacoma, Washington, Forente stater, 98405
- Har ikke rekruttert ennå
- Northwest Medical Specialties, PLLC
-
Ta kontakt med:
- Jorge Chaves
-
-
-
-
-
Beijing, Kina
- Rekruttering
- Peking University First Hospital
-
Ta kontakt med:
- Shikai Wu
- Telefonnummer: +86 18910715326
- E-post: skywu4329@sina.com
-
Ta kontakt med:
- Yu Fan
-
Changsha, Kina
- Rekruttering
- Hunan Cancer Hospital
-
Ta kontakt med:
- Quchang Oyang
- Telefonnummer: 0731-89762161
- E-post: Oyqc1969@126.com
-
Guangzhou, Kina
- Rekruttering
- Sun Yat-sen University Cancer Center
-
Ta kontakt med:
- Shusen Wang
- Telefonnummer: 020-87342693
- E-post: Wangshus@susucc.org.cn
-
Hefei, Kina
- Rekruttering
- The First Affiliated Hospital of Anhui Medical University
-
Ta kontakt med:
- Yingying Du
- Telefonnummer: 0551-65908511
- E-post: duyy1980@126.com
-
Shanghai, Kina
- Rekruttering
- Fudan University Shanghai Cancer Center
-
Ta kontakt med:
- Jian Zhang
-
Ta kontakt med:
- Xiaohua Wu
- Telefonnummer: 18121299168
- E-post: wu.xh@fudan.edu.cn
-
Shenyang, Kina
- Rekruttering
- The First Hospital of China Medical University
-
Ta kontakt med:
- Funan Liu
- Telefonnummer: 13609877906
- E-post: lfn_clinical@126.com
-
Zhengzhou, Kina
- Rekruttering
- Henan Cancer Hospital
-
Ta kontakt med:
- Min Yan
- Telefonnummer: +86 157 1385 7388
- E-post: ym200678@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed unresectable advanced or metastatic disease.
- Have at least one measurable lesion per RECIST v1.1;
- Life expectancy ≥ 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
- Weight ≥ 35 kg;
Exclusion Criteria:
- An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.
- Use of strong inhibitors or strong inducers of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;
- Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);
- Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be clinically significant;
- Spinal cord compression, leptomeningeal disease, or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;
- Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study drug(s);
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part A(Phase I)
Dose Escalation |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
|
Eksperimentell: Part B(Phase IIa)
Dose Expansion/Dose Optimization |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Tidsramme: Approximately 12 months
|
At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251 |
Approximately 12 months
|
|
Recommended doses for expansion (RDE)
Tidsramme: Approximately 12 months
|
The RDE will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data, such as chronic toxicities, discontinuations, or withdrawals for toxicity that occur beyond the DLT period; PK data collected at the time of evaluation; Preliminary efficacy data. |
Approximately 12 months
|
|
Overview of Treatment-emergent Adverse Events (TEAEs)
Tidsramme: Approximately 24 months
|
All TEAEs will be graded according to NCI CTCAE v6.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA). |
Approximately 24 months
|
|
Objective Response Rate (ORR)
Tidsramme: At least 6 weeks post dose of first participant up to approximately 24 months
|
ORR is defined as the proportion of participants with Best objective response (BOR) of confirmed complete response (CR) or partial response (PR), as per investigator's assessment according to RECIST v1.1. |
At least 6 weeks post dose of first participant up to approximately 24 months
|
|
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251
Tidsramme: Approximately 12 months
|
The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data. |
Approximately 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Disease control rate (DCR)
Tidsramme: Approximately 2 years
|
The proportion of participants with BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting at least 5 weeks. |
Approximately 2 years
|
|
Duration of response (DoR)
Tidsramme: Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first occurrence of objective tumor response (CR or PR) to the date of first radiographic PD or death due to any cause. |
Approximately 2 years
|
|
Time to response (TTR)
Tidsramme: Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first dose of study dose to the first occurrence of objective tumor response (CR or PR) |
Approximately 2 years
|
|
Progression-free survival (PFS)
Tidsramme: Approximately 2 years
|
The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first. |
Approximately 2 years
|
|
Overall survival (OS)
Tidsramme: Approximately 2 years
|
Every 12 weeks (± 7 days) until death, withdrawal of consent for follow-up, lost to follow-up or end of study, whichever occurs first. |
Approximately 2 years
|
|
Maximum plasma/serum concentration (Cmax)
Tidsramme: Cycle 1 and Cycle 3 (21-day cycle)
|
Observed maximum plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609; only applies to Cycles 1 and 3. |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Time to maximum plasma/serum concentration (Tmax)
Tidsramme: Cycle 1 and Cycle 3 (21-day cycle)
|
Time to observed Cmax for HMPL-A251, total anti-HER2 antibody, and HM5041609 |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Area under the plasma/serum concentration-time curve (AUC)
Tidsramme: Cycle 1 and Cycle 3 (21-day cycle)
|
Derived from the observed plasma/serum concentration-time data for HMPL-A251, total anti-HER2 antibody, and HM5041609 using noncompartmental analysis |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Pre-dose plasma/serum concentration (Cmin)
Tidsramme: Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
Observed pre-dose plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609. |
Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
|
Immunogenicity of HMPL-A251
Tidsramme: Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Incidence of anti-drug antibody and neutralizing antibody against HMPL-A251 |
Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2025-251-GLOB1
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .